Clearmind Medicine Initiates Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder at Yale School of Medicine

1.5 min readPublished On: May 25th, 2023By

LOS ANGELES– Clearmind Medicine Inc. has selected Yale School of Medicine as the first site in the United States for its Phase I/IIa clinical trial of CMND-100, a proprietary compound aimed at treating alcohol use disorder (AUD). The trial will assess the safety and efficacy of CMND-100, which contains the active ingredient MEAI (5-methoxy-2-aminoindane), a psychoactive compound of the aminoindane class.

During the clinical trial, participants will receive oral capsules of CMND-100 once daily for ten consecutive days. They will then report their drinking patterns and alcohol cravings throughout the trial period. The primary objective of the trial is to determine the tolerable dose and evaluate the safety and pharmacokinetics/pharmacodynamics of single and repeated doses of CMND-100 in both healthy subjects and individuals with AUD. The secondary endpoint will assess the efficacy of CMND-100 in reducing drinking patterns and cravings in individuals with moderate-to-severe AUD.

Anahita Bassir Nia, an expert in substance abuse, including alcohol abuse, will lead the trial at Yale School of Medicine. Clearmind’s CEO, Dr. Adi Zuloff-Shani, expressed confidence in the collaboration, seeing it as validation of CMND-100’s potential as a treatment for AUD.

Clearmind recently received approval from the Ethics Committee of Israel’s IMCA center for the Phase I/IIa clinical trial of CMND-100. The trial, known as CM-CMND-001, is a multinational, multicenter study that will assess the tolerability, safety, and pharmacokinetics of single and multiple doses of CMND-100 in healthy volunteers and individuals with AUD.

With an extensive intellectual property portfolio and a renowned advisory board of psychiatrists and researchers, Clearmind believes CMND-100 has the potential to revolutionize addiction and mental health treatment. The company aims to provide an innovative, self-administered, non-addictive prescription pill that offers immediate therapeutic benefits without the need for expensive therapies.

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News